 |
|
|
| |
Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 48 Subgroup Analysis in Randomised Cohort Participants
|
| |
| |
Reported by Jules Levin
Glasgow 2018 Oct 27-31
J.-M. Molina,1J. Aberg,2I. Cassetti,3M. Kozal,4G. Latiff,5J. Lalezari,6G. Pialoux,7A. Streinu-Cercel,8M. Gummel,9A. Pierce,10P. Ackerman,11C. Llamoso,11M. Lataillade11
1Hôpital Saint-Louis, APHP and University of Paris Diderot Paris, Infectious Diseases, Paris, France; 2Icahn School of Medicine at Mount Sinai, Infectious Diseases, New York, NY, USA; 3Helios Salud, Ambulatory AIDS Care Center, Infectious Diseases, Buenos Aires, Argentina; 4Yale University School of Medicine, Infectious Diseases, New Haven, CT, USA; 5Maxwell Centre, Infectious Diseases, Durban, South Africa; 6Quest Research, Internal Medicine, San Francisco, CA, USA; 7Hôpital Tenon, Infectious Diseases, Paris, France; 8Carol Davila University of Medicine and Pharmacy, Infectious Diseases, Bucharest, Romania; 9GlaxoSmithKline Statistics, Upper Providence, Philadelphia, PA, USA; 10ViiV Healthcare Clinical Development, Research Triangle Park, NC, USA; 11ViiV Healthcare Clinical Development Branford, CT, USA
|
| |
|
|
|
|
|
